Cenforce 200 mg
However, sildenafil tablets may be taken anywhere from 30 minutes to 4 hours before sexual activity (2.1) •Based on effectiveness and toleration, may increase to a maximum of 100 mg or decrease to 25 mg (2.1) •Maximum recommended dosing frequency is once per day (2.1) Tablets: 25 mg, 50 mg, 100 mg (3) •Administration of sildenafil tablets to patients using nitric oxide donors, such as organic nitrates or organic nitrites in any form. Sildenafil tablets were shown to potentiate the hypotensive effect of nitrates ( 4.1, 7.1, 12.2) •Known hypersensitivity to sildenafil or any component of tablet (4.2) •Administration with guanylate cyclase (GC) stimulators, such as riociguat (4.3) •Patients should not use sildenafil tablets if sexual activity is inadvisable due to cardiovascular status (5.1) •Patients should seek emergency treatment if an erection lasts >4 hours. Use sildenafil tablets with caution in patients predisposed to priapism (5.2) •Patients should stop sildenafil tablets and seek medical care if a sudden loss of vision occurs in one or both eyes, which could be a sign of non arteritic anterior ischemic optic neuropathy (NAION).
8. Use In Specific Populations
Such an event may be a signof non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision including permanent loss of vision, that has been reported rarely post-marketing in temporal associationwith theuse of all PDE5 inhibitors. Based on published literature, the annual incidence of NAION is 2.5 to 11.8 cases per 100,000 in males aged ≥ 50.An observationalcase-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period. Theresults suggestan approximate 2-fold increase in the risk of NAION, with a risk estimate of 2.15 (95% CI 1.06, 4.34). Other risk factors for NAION,such as the presence of ''crowded'' optic disc, may have contributed to the occurrence of NAION in these studies. Neither the rare post-marketing reports, nor the association of PDE5 inhibitor use and NAION in theobservationalstudies, substantiate a causal relationship between PDE5 inhibitor use and NAION [see Adverse Reactions(6.2)].
8.2 Lactation
Therefore, PDE5 inhibitors, including sildenafil tablets, should be used with caution in these patients and only when the anticipated benefits outweigh the risks. Individuals with ''crowded'' optic disc are also considered at greater risk for NAION compared to the general population, however, evidence is insufficient to support screening of prospective users of PDE5 inhibitors, including sildenafil tablets, for this uncommon condition. There are no controlled clinical data on the safety or efficacy of sildenafil tablets in patients with retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases); if prescribed, this should be done with caution. Physicians should advise patients to stop taking PDE5 inhibitors, including sildenafil tablets, and seek prompt medical attention in the event of sudden decrease or loss of hearing.
Interaction with Food and Other Medications
Patients with a”crowded” optic disc may also be at an increased risk of NAION.
| Product | Dosage | Quantity + Bonus | Price | |
|---|---|---|---|---|
| Viagra Generic | 150mg | 120 + 8 Pills | 177.58€ 169.12€ | |
| Viagra Generic | 50mg | 20 Pills | 40.52€ 38.59€ | |
| Viagra Generic | 50mg | 270 + 8 Pills | 198.48€ 189.03€ | |
| Viagra Generic | 50mg | 120 + 6 Pills | 129.64€ 123.47€ | |
| Viagra Generic | 150mg | 360 + 10 Pills | 423.48€ 403.31€ | |
| Viagra Generic | 25mg | 270 + 8 Pills | 184.26€ 175.49€ | |
| Viagra Generic | 25mg | 20 Pills | 37.74€ 35.94€ | |
| Kamagra Polo | 100mg | 60 + 4 Pills | 189.39€ 180.37€ | |
| Viagra Generic | 25mg | 60 + 4 Pills | 71.99€ 68.56€ | |
| Kamagra Soft Tabs | 100mg | 120 + 6 Pills | 311.78€ 296.93€ | |
| Kamagra Oral Jelly | 100mg | 63 + 7 Sachets | 224.18€ 213.50€ | |
| Kamagra | 100mg | 180 + 6 Pills | 436.79€ 415.99€ | |
| Kamagra Polo | 100mg | 180 + 8 Pills | 446.52€ 425.26€ | |
| Kamagra | 100mg | 60 + 4 Pills | 201.34€ 191.75€ |
(5.3) •Patients should stop sildenafil tablets and seek prompt medical attention in the event of sudden decrease or loss of hearing (5.4) •Caution is advised when sildenafil tablets are co-administered with alpha-blockers or anti-hypertensives. Concomitant use may lead to hypotension (5.5) •Decreased blood pressure, syncope, and prolonged erection may occur at higher sildenafil exposures.
Lifestyle Adjustments for Enhancing Effectiveness
However, sildenafil tablets may be taken anywhere from 30 minutes to 4 hours before sexual activity (2.1) •Based on effectiveness and toleration, may increase to a maximum of 100 mg or decrease to 25 mg (2.1) •Maximum recommended dosing frequency is once per day (2.1) Tablets: 25 mg, 50 mg, 100 mg (3) •Administration of sildenafil tablets to patients using nitric oxide donors, such as organic nitrates or organic nitrites in any form. Sildenafil tablets were shown to potentiate the hypotensive effect of nitrates ( 4.1, 7.1, 12.2) •Known hypersensitivity to sildenafil or any component of tablet (4.2) •Administration with guanylate cyclase (GC) stimulators, such as riociguat (4.3) •Patients should not use sildenafil tablets if sexual activity is inadvisable due to cardiovascular status (5.1) •Patients should seek emergency treatment if an erection lasts >4 hours. Use sildenafil tablets with caution in patients predisposed to priapism (5.2) •Patients should stop sildenafil tablets and seek medical care if a sudden loss of vision occurs in one or both eyes, which could be a sign of non arteritic anterior ischemic optic neuropathy (NAION). Patients with a”crowded” optic disc may also be at an increased risk of NAION. (5.3) •Patients should stop sildenafil tablets and seek prompt medical attention in the event of sudden decrease or loss of hearing (5.4) •Caution is advised when sildenafil tablets are co-administered with alpha-blockers or anti-hypertensives.
Frequently Asked Questions
Concomitant use may lead to hypotension (5.5) •Decreased blood pressure, syncope, and prolonged erection may occur at higher sildenafil exposures. Decrease in sildenafil tablets dosage is recommended (2.4,5.6) Most common adverse reactions (≥ 2%) include headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness and rash (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Evaric Pharmaceuticals, Inc. at 1-866-495-1995 or FDA at 1-800-FDA-1088 or •Sildenafil tablets can potentiate the hypotensive effects of nitrates, alpha blockers, and anti-hypertensives ( 4.1, 5.5, 7.1, 7.2, 7.3, 12.2) •With concomitant use of alpha blockers, initiate sildenafil tablets at 25 mg dose (2.3) •CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin): Increase sildenafil tablets exposure (2.4, 7.4,12.3) •Ritonavir: Do not exceed a maximum single dose of 25 mg in a 48 hour period ( 2.4, 5.6) •Erythromycin or strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, saquinavir): Consider a starting dose of 25 mg (2.4,7.4) Sildenafil tablets are indicated for the treatment of erectile dysfunction. Based on effectiveness and toleration, the dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg. Sildenafil tablets were shown to potentiate the hypotensive effects of nitrates and its administration in patients who use nitric oxide donors such as organic nitrates or organic nitrites in any form is therefore contraindicated [see Contraindications (4.1),Drug Interactions (7.1),and Clinical Pharmacology (12.2)].
Sildenafil Tablets Dosage and Administration
When sildenafil tablets are co-administered with an alpha-blocker, patients should be stable on alpha-blocker therapy prior to initiating sildenafil tablets treatment and sildenafil tablets should be initiated at 25 mg [see Warnings and Precautions (5.5),Drug Interactions (7.2),and Clinical Pharmacology (12.2)]. Ritonavir The recommended dose for ritonavir-treated patients is 25 mg prior to sexual activity and the recommended maximum women sildenafil dose is 25 mg within a 48 hour period because concomitant administration increased the blood levels of sildenafil by 11-fold [see Warnings and Precautions (5.6),Drug Interactions (7.4),and Clinical Pharmacology (12.3)]. CYP3A4 Inhibitors Consider a starting dose of 25 mg in patients treated with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or saquinavir) or erythromycin. Clinical data have shown that co-administration with saquinavir or erythromycin increased plasma levels of sildenafil by about 3 fold [see Drug Interactions (7.4)and Clinical Pharmacology (12.3)]. Consider a starting dose of 25 mg in patients > 65 years, patients with hepatic impairment (e.g., cirrhosis), and patients with severe renal impairment (creatinine clearance <30 mL/minute) because administration of sildenafil tablets in these patients resulted in higher plasma levels of sildenafil [see Use in Specific Populations ( 8.5, 8.6, 8.7)and Clinical Pharmacology ( 12.3)]. Decrease in sildenafil tablets dosage is recommended (2.4,5.6) Most common adverse reactions (≥ 2%) include headache, flushing, dyspepsia, abnormal vision, nasal congestion, back pain, myalgia, nausea, dizziness and rash (6.1) To report SUSPECTED ADVERSE REACTIONS, contact Evaric Pharmaceuticals, Inc. at 1-866-495-1995 or FDA at 1-800-FDA-1088 or •Sildenafil tablets can potentiate the hypotensive effects of nitrates, alpha blockers, and anti-hypertensives ( 4.1, 5.5, 7.1, 7.2, 7.3, 12.2) •With concomitant use of alpha blockers, initiate sildenafil tablets at 25 mg dose (2.3) •CYP3A4 inhibitors (e.g., ritonavir, ketoconazole, itraconazole, erythromycin): Increase sildenafil tablets exposure (2.4, 7.4,12.3) •Ritonavir: Do not exceed a maximum single dose of 25 mg in a 48 hour period ( 2.4, 5.6) •Erythromycin or strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, saquinavir): Consider a starting dose of 25 mg (2.4,7.4) Sildenafil tablets are indicated for the treatment of erectile dysfunction. Based on effectiveness and toleration, the dose may be increased to a maximum recommended dose of 100 mg or decreased to 25 mg.
| Interacting Drug/Class | Effect on Sildenafil | Clinical Significance | Recommendations |
|---|---|---|---|
| Nitrates | Potentiates vasodilation | Risk of severe hypotension | Avoid concomitant use |
| CYP3A4 inhibitors (e.g., Ritonavir) | Increase sildenafil plasma levels | Risk of increased side effects | Reduce dose or avoid |
| Alpha-blockers | Additive blood pressure lowering | Hypotension | Use with caution, monitor BP |
| CYP3A4 inducers (e.g., Rifampin) | Decrease sildenafil effectiveness | May reduce efficacy | Adjust dose accordingly |
Sildenafil tablets were shown to potentiate the hypotensive effects of nitrates and its administration in patients who use nitric oxide donors such as organic nitrates or organic nitrites in any form is therefore contraindicated [see Contraindications (4.1),Drug Interactions (7.1),and Clinical Pharmacology (12.2)]. When sildenafil tablets are co-administered with an alpha-blocker, patients should be stable on alpha-blocker therapy prior to initiating sildenafil tablets treatment and sildenafil tablets should be initiated at 25 mg [see Warnings and Precautions (5.5),Drug Interactions (7.2),and Clinical Pharmacology (12.2)].
12.2 Pharmacodynamics
Tadalafil (Generic Cialis)
Key takeaways
Ritonavir The recommended dose for ritonavir-treated patients is 25 mg prior to sexual activity and the recommended maximum women sildenafil dose is 25 mg within a 48 hour period because concomitant administration increased the blood levels of sildenafil by 11-fold [see Warnings and Precautions (5.6),Drug Interactions (7.4),and Clinical Pharmacology (12.3)].
- Sildenafil 200 mg's safety profile depends on individual health conditions.
- It is important to inform your doctor of all medications being taken.
- Use sildenafil only when needed for sexual activity.
- Avoid engaging in activities that require alertness until effects are known.
- The drug is often part of a broader erectile dysfunction treatment strategy.
- Safe storage is essential to prevent accidental ingestion by children or others.
CYP3A4 Inhibitors Consider a starting dose of 25 mg in patients treated with strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, or saquinavir) or erythromycin. Clinical data have shown that co-administration with saquinavir or erythromycin increased plasma levels of sildenafil by about 3 fold [see Drug Interactions (7.4)and Clinical Pharmacology (12.3)]. Consider a starting dose of 25 mg in patients > 65 years, patients with hepatic impairment (e.g., cirrhosis), and patients with severe renal impairment (creatinine clearance <30 mL/minute) because administration of sildenafil tablets in these patients resulted in higher plasma levels of sildenafil [see Use in Specific Populations ( 8.5, 8.6, 8.7)and Clinical Pharmacology ( 12.3)]. Sildenafil Tablets USP, 25 mg are white colored, round-shaped, biconvex, film coated tablets debossed with 'E' on one side and '113' on the other side. Sildenafil Tablets USP, 50 mg are white colored, round-shaped, biconvex, film coated tablets debossed with 'E' on one side and '114' on the other side. Sildenafil Tablets USP, 100 mg are white colored, round-shaped, biconvex, film coated tablets debossed with 'E' on one side and '115' on the other side. Consistent with its known effects on the nitric oxide/cGMP pathway [see Clinical Pharmacology ( 12.1, 12.2)] ,sildenafil tablets were shown to potentiate the hypotensive effects of nitrates, and its administration to patients who are using nitric oxide donors such as organic nitrates or organic nitrites in any form either regularly and/or intermittently is therefore contraindicated. After patients have taken sildenafil tablets, it is unknown when nitrates, if necessary, can be safely administered. Although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be safely co-administered at this time point [see Dosage and Administration (2.3),Drug Interactions (7.1),and Clinical Pharmacology (12.2)]. Hypersensitivity reactions have been reported, including rash and urticaria [see Adverse Reactions (6.1)].
| Use Case | Patient Group | Effect Duration | Common Side Effects |
|---|---|---|---|
| Erectile Dysfunction | Men aged 40-70 | 4-6 hours | Headache, flushing, nasal congestion |
| Pulmonary Hypertension | Adults with PAH | 4-6 hours | Dizziness, visual disturbances |
| Off-label Sexual Enhancement | Men over 40 | Varies | Muscle aches, digestive upset |
| Sildenafil for High Altitude Sickness | Travelers | 4-6 hours | Low blood pressure, dizziness |
Therefore, treatments for erectile dysfunction, including sildenafil tablets, should not be generally sildenafil 130mg used in men for whom sexual activity is inadvisable because of their underlying cardiovascular status.
1. Indications and Usage for Sildenafil Tablets
Sildenafil Tablets USP, 25 mg are white colored, round-shaped, biconvex, film coated tablets debossed with 'E' on one side and '113' on the other side. Sildenafil Tablets USP, 50 mg are white colored, round-shaped, biconvex, film coated tablets debossed with 'E' on one side and '114' on the other side. Sildenafil Tablets USP, 100 mg are white colored, round-shaped, biconvex, film coated tablets debossed with 'E' on one side and '115' on the other side. Consistent with its known effects on the nitric oxide/cGMP pathway [see Clinical Pharmacology ( 12.1, 12.2)] ,sildenafil tablets were shown to potentiate the hypotensive effects of nitrates, and its administration to patients who are using nitric oxide donors such as organic nitrates or organic nitrites in any form either regularly and/or intermittently is therefore contraindicated. After patients have taken sildenafil tablets, it is unknown when nitrates, if necessary, can be safely administered.
Viagra strengths
Although plasma levels of sildenafil at 24 hours post dose are much lower than at peak concentration, it is unknown whether nitrates can be safely co-administered at this time point [see Dosage and Administration (2.3),Drug Interactions (7.1),and Clinical Pharmacology (12.2)]. Hypersensitivity reactions have been reported, including rash and urticaria [see Adverse Reactions (6.1)]. Therefore, treatments for erectile dysfunction, including sildenafil tablets, should not be generally sildenafil 130mg used in men for whom sexual activity is inadvisable because of their underlying cardiovascular status. Sildenafil tablets have systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers (mean maximum decrease of 8.4/5.5 mmHg), [see Clinical Pharmacology (12.2)].While this normally would be expected to be of little consequence in most patients, prior to prescribing sildenafil tablets, physicians should carefully consider whether their patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects, especially in combination with sexual activity. Use with caution in patients with the following underlying conditions which can be particularly sensitive to the actions of vasodilators including sildenafil tablets – those with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure.
What’s the difference between sildenafil 50 mg and 100 mg?
There are no controlled clinical data on the safety or efficacy of sildenafil tablets in the following groups; if prescribed, this should be done with caution. •Patients who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within sildenafil tables the last 6 months; •Patients with resting hypotension (BP <90/50 mmHg) or hypertension (BP >170/110 mmHg); •Patients with cardiac failure or coronary artery disease causing unstable angina. Sildenafil tablets should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia). However, there are no controlled clinical data on the safety or efficacy of sildenafil tablets in patients with sickle cell or related anemias. Physicians should advise patients to stop use of all phosphodiesterase type 5 (PDE5) inhibitors, including sildenafil tablets, and seek medical attention in the event of a sudden loss of vision in one or both eyes. Sildenafil tablets have systemic vasodilatory properties that resulted in transient decreases in supine blood pressure in healthy volunteers (mean maximum decrease of 8.4/5.5 mmHg), [see Clinical Pharmacology (12.2)].While this normally would be expected to be of little consequence in most patients, prior to prescribing sildenafil tablets, physicians should carefully consider whether their patients with underlying cardiovascular disease could be affected adversely by such vasodilatory effects, especially in combination with sexual activity. Use with caution in patients with the following underlying conditions which can be particularly sensitive to the actions of vasodilators including sildenafil tablets – those with left ventricular outflow obstruction (e.g., aortic stenosis, idiopathic hypertrophic subaortic stenosis) and those with severely impaired autonomic control of blood pressure.
- Sildenafil 200 mg can be used by men aged 18 and above.
- It is important to report any history of heart problems before use.
- Alcohol consumption may diminish the effectiveness of sildenafil.
- Sildenafil 200 mg provides longer-lasting erections compared to lower doses.
- Abstain from driving or operating machinery if experiencing dizziness.
- Using sildenafil without medical advice increases health risks.
There are no controlled clinical data on the safety or efficacy of sildenafil tablets in the following groups; if prescribed, this should be done with caution. •Patients who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within sildenafil tables the last 6 months; •Patients with resting hypotension (BP <90/50 mmHg) or hypertension (BP >170/110 mmHg); •Patients with cardiac failure or coronary artery disease causing unstable angina. Sildenafil tablets should be used with caution in patients with anatomical deformation of the penis (such as angulation, cavernosal fibrosis or Peyronie's disease), or in patients who have conditions which may predispose them to priapism (such as sickle cell anemia, multiple myeloma, or leukemia). However, there are no controlled clinical data on the safety or efficacy of sildenafil tablets in patients with sickle cell or related anemias. Physicians should advise patients to stop use of all phosphodiesterase type 5 (PDE5) inhibitors, including sildenafil tablets, and seek medical attention in the event of a sudden loss of vision in one or both eyes. Such an event may be a signof non-arteritic anterior ischemic optic neuropathy (NAION), a rare condition and a cause of decreased vision including permanent loss of vision, that has been reported rarely post-marketing in temporal associationwith theuse of all PDE5 inhibitors.
5.8 Effects on Bleeding
Based on published literature, the annual incidence of NAION is 2.5 to 11.8 cases per 100,000 in males aged ≥ 50.An observationalcase-crossover study evaluated the risk of NAION when PDE5 inhibitor use, as a class, occurred immediately before NAION onset (within 5 half-lives), compared to PDE5 inhibitor use in a prior time period.
Before Using
Theresults suggestan approximate 2-fold increase in the risk of NAION, with a risk estimate of 2.15 (95% CI 1.06, 4.34). Other risk factors for NAION,such as the presence of ''crowded'' optic disc, may have contributed to the occurrence of NAION in these studies. Neither the rare post-marketing reports, nor the association of PDE5 inhibitor use and NAION in theobservationalstudies, substantiate a causal relationship between PDE5 inhibitor use and NAION [see Adverse Reactions(6.2)]. Therefore, PDE5 inhibitors, including sildenafil tablets, should be used with caution in these patients and only when the anticipated benefits outweigh the risks. Individuals with ''crowded'' optic disc are also considered at greater risk for NAION compared to the general population, however, evidence is insufficient to support screening of prospective users of PDE5 inhibitors, including sildenafil tablets, for this uncommon condition. There are no controlled clinical data on the safety or efficacy of sildenafil tablets in patients with retinitis pigmentosa (a minority of these patients have genetic disorders of retinal phosphodiesterases); if prescribed, this should be done with caution.
| Patient Group | Recommended Dosage | Administration Tips | Contraindications |
|---|---|---|---|
| Adult Men with ED | 200 mg once daily | Take 30-60 min before activity | Nitrate medication use, severe liver impairment |
| Pulmonary Hypertension | 20 mg three times daily | Take with water, on an empty stomach | Concurrent use of compatible medications |
| Elderly Patients | Start with lower doses | Adjust based on response | Liver or kidney impairment |
| Patients with Kidney Disease | Dose adjustment may be needed | Follow physician instructions | Severe renal impairment |
Physicians should advise patients to stop taking PDE5 inhibitors, including sildenafil tablets, and seek prompt medical attention in the event of sudden decrease or loss of hearing.